Xcout Intel
Soligenix, Inc.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
Subscribe to see Soligenix, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Soligenix, Inc. at a glance
Soligenix, Inc. is a biopharmaceuticals company headquartered in Princeton, United States. It is publicly listed (SNGX) with a market capitalisation of $5.9M. Xcout tracks 17 named people at Soligenix, Inc., including Christopher J. Schaber (Chairman of the Board of Directors, Chief Executive Officer & President).
Soligenix, Inc. leadership
- Christopher J. SchaberChairman of the Board of Directors, Chief Executive Officer & President
- Jonathan L. Guarino CGMASenior Vice President, Chief Financial Officer & Corporate Secretary
- Oreola DoniniSenior Vice President & Chief Scientific Officer
- Adam T. RumageSenior VP of Project Management & Regulatory Affairs
- Anthony Gregg LapointeDirector
- Christopher J. SchaberDirector
11 more named people on record for Soligenix, Inc., with roles, board committees and tenure — see the full roster →
Get Soligenix, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Soligenix, Inc. in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access